Japan sets up panel to appraise fee revision

14 May 2006

Japan's Chuikyo (Central Social Insurance and Medical Council) has approved the establishment of a sub-panel which will appraise the implementation/achievements and effects in the revision and newly-inaugurated items including issuing receipts indicating specific medical treatments, management of nicotine addiction or smoking cessation, measurement of medical safety and substitution of branded drugs to generic drugs in the 2006 medical fee revisions. This is in order to allow the Japanese polulation to grasp the progress and results of the medical fee revisions at its general meeting in April 19.

Among other things, the number of physicians' checks (approvals) in a column on a prescription format allowing pharmacist to change generic drugs (depending on patients' request) and the number of people who have changed branded products to generics will be appraised.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight